SRX Global Valuation Multiples
SRX Global is valued at $16M as of November 2026, a 3.0x revenue multiple. In the last fiscal year, SRX Global revenue was $7M and SRX Global EBITDA was ($8M).
SRX Global Overview
About SRX Global
SRX Global Inc Formerly SRX HealthSolutions Inc operates the continuing pet health and wellness business under the Halo brand, offering premium and super-premium foods, treats, toppers, chews, dental products and supplements for dogs and cats. The company provides high-quality pet products formulated to meet high-quality sourcing and nutritional standards and produced through co-manufacturing relationships. Its Consumer Products segment includes the legacy Halo pet food business with premium products such as dry kibble, wet food, freeze-dried raw food, treats and toppers. Products are sold across e-commerce platforms such as Amazon and Chewy, select retail partners, and international distributors, with operations mainly in the United States, Taiwan and other markets.
Founded
2013
HQ
Employees
11
Website
N/A
Financials (Last FY)
EV
$20M
Valuation Multiples
Start free trial
SRX Global Financials
SRX Global reported last fiscal year revenue of $7M and negative EBITDA of ($8M).
In the same fiscal year, SRX Global generated $2M in gross profit, ($8M) in EBITDA losses, and had net loss of ($45M).
Revenue (LTM)
SRX Global P&L
In the most recent fiscal year, SRX Global reported revenue of $7M and EBITDA of ($8M).
SRX Global is unprofitable as of last fiscal year, with gross margin of 23%, EBITDA margin of (122%), and net margin of (689%).
Financial data powered by Morningstar, Inc.
SRX Global Stock Performance
SRX Global has current market cap of $16M, and enterprise value of $20M.
Market Cap Evolution
SRX Global's stock price is $0.81.
SRX Global share price decreased by 19.6% in the last 30 days, and by 96.0% in the last year.
SRX Global has an EPS (earnings per share) of $-2.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20M | $16M | 0.0% | -19.6% | -51.7% | -96.0% | $-2.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSRX Global Valuation Multiples
SRX Global trades at 3.0x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
SRX Global Financial Valuation Multiples
As of November 8, 2026, SRX Global has market cap of $16M and EV of $20M.
SRX Global has a P/E ratio of (0.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SRX Global Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SRX Global Margins & Growth Rates
In the most recent fiscal year, SRX Global reported gross margin of 23%, EBITDA margin of (122%), and net margin of (689%).
SRX Global Margins
SRX Global Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
SRX Global Operational KPIs
SRX Global's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
SRX Global Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all SRX Global competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by SRX Global
SRX Global has acquired 1 company to date.
Last acquisition by SRX Global was on October 6th 2026. SRX Global acquired CERo Therapeutics Holdings for $11M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by SRX Global
| Description | CERo Therapeutics is a clinical-stage US biotechnology company, based in South San Francisco, California, that develops cell therapies for cancer. The operating company was founded in 2016 and became publicly traded in 2024 through a business combination with a special purpose acquisition company, forming CERo Therapeutics Holdings. Its mission is to build curative therapies that combine several forms of tumour clearance in a single T cell. Its CER T-cell platform engineers T cells to join the innate and adaptive immune responses, with potential in blood cancers and solid tumours. The lead candidate, CER-1236, is an autologous T-cell therapy studied in an early-stage clinical trial. As a development-stage company it has no product revenue and would earn money by licensing or partnering programmes or, later, by selling approved therapies. |
| HQ Country | |
| HQ City | South San Francisco |
| Deal Date | 6 Oct 2026 |
| Valuation | $11M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all SRX Global acquisitions and their M&A valuation multiples. Start Free Trial | |
Investments by SRX Global
SRX Global has invested in 1 company to date.
Latest investment by SRX Global was on June 22nd 2026. SRX Global invested in ARMR Sciences in their Strategic investment round.
Latest Investments by SRX Global
| Description | ARMR Sciences is a developer of immunotherapy-based biodefense solutions to prevent overdose from fentanyl and synthetic drugs. ARMR Sciences maintains a platform for scalable, long-acting immunity against emerging narcotic and chemical threats with backing from Department of Defense licenses and federal health agencies. |
| HQ Country | |
| HQ City | New York City, NY |
| Deal Date | 22 Jun 2026 |
| Round | Strategic investment |
| Raised | undisclosed |
| Investors | SRX Global |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all SRX Global investments and their VC round multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SRX Global
| When was SRX Global founded? | SRX Global was founded in 2013. |
| Where is SRX Global headquartered? | SRX Global is headquartered in United States. |
| How many employees does SRX Global have? | As of today, SRX Global has over 11 employees. |
| Who is the CEO of SRX Global? | SRX Global's CEO is Kent Cunningham. |
| Is SRX Global publicly listed? | Yes, SRX Global is a public company listed on NYSE American. |
| What is the stock symbol of SRX Global? | SRX Global trades under SRXH ticker. |
| When did SRX Global go public? | SRX Global went public in 2025. |
| Who are competitors of SRX Global? | SRX Global main competitors include |
| What is the current market cap of SRX Global? | SRX Global's current market cap is $16M. |
| What is the current revenue of SRX Global? | SRX Global's last fiscal year revenue is $7M. |
| What is the current EV/Revenue multiple of SRX Global? | Current revenue multiple of SRX Global is 3.0x. |
| Is SRX Global profitable? | No, SRX Global is not profitable. |
| How many companies SRX Global has acquired to date? | As of November 2026, SRX Global has acquired 1 company. |
| What was the largest acquisition by SRX Global? | $11M acquisition of CERo Therapeutics Holdings on 6th October 2026 was the largest M&A SRX Global has done to date. |
| What companies SRX Global acquired? | SRX Global acquired CERo Therapeutics Holdings. |
| In how many companies SRX Global has invested to date? | As of November 2026, SRX Global has invested in 1 company. |
| What was the last SRX Global investment? | On 22nd June 2026 SRX Global invested in ARMR Sciences, participating in a Strategic investment round. |
| In what companies SRX Global invested in? | SRX Global invested in ARMR Sciences. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.